Home » Stocks » ZIOP

ZIOPHARM Oncology Inc. (ZIOP)

Stock Price: $3.03 USD -0.04 (-1.30%)
Updated May 13, 2021 4:00 PM EDT - Market closed
After-hours: $3.11 +0.08 (2.64%) May 13, 7:57 PM
Market Cap 647.65M
Revenue (ttm) n/a
Net Income (ttm) -83.24M
Shares Out 215.52M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $3.03
Previous Close $3.07
Change ($) -0.04
Change (%) -1.30%
Day's Open 3.10
Day's Range 2.98 - 3.15
Day's Volume 1,835,863
52-Week Range 2.06 - 5.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Annual shareholder meeting planned for May 19, 2021

1 week ago - GlobeNewsWire

Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event Panel Discussion and Presentation part of Future of Cell and Gene Therapies Event

1 week ago - GlobeNewsWire

Annual shareholder meeting to be held on May 19, 2021 Annual shareholder meeting to be held on May 19, 2021

2 weeks ago - GlobeNewsWire

BOSTON and HOUSTON and TAIPEI, Taiwan, April 19, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that in March, the first patient was infus...

3 weeks ago - GlobeNewsWire

Adds to growing body of published research supporting the development of non-viral TCR-T therapies for the treatment of epithelial cancers Adds to growing body of published research supporting the devel...

1 month ago - GlobeNewsWire

Shares are dropping after an analyst's downgrade.

2 months ago - The Motley Fool

Investors reacted positively to FDA clearance to begin a clinical study and Ziopharm's CEO change.

2 months ago - The Motley Fool

Company to Hold R&D Day on Thursday, March 11, 2021 Company to Hold R&D Day on Thursday, March 11, 2021

2 months ago - GlobeNewsWire

An ugly board of directors skirmish came to an end.

3 months ago - The Motley Fool

BOSTON, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effec...

3 months ago - GlobeNewsWire

– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation –

3 months ago - GlobeNewsWire

BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is...

4 months ago - GlobeNewsWire

– Advances Eden BioCell's clinical program to validate Rapid Personalized Manufacturing (RPM) –

4 months ago - GlobeNewsWire

Investors need to pay close attention to Ziopharm (ZIOP) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), a sizable and long-term shareholder of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm”...

4 months ago - Business Wire

Jaime Vieser and Holger Weis Elected to Board of Directors Jaime Vieser and Holger Weis Elected to Board of Directors

4 months ago - GlobeNewsWire

BOSTON, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed t...

4 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today responded to the latest element of the low-road campaign that Ziopharm Oncology, Inc...

5 months ago - Business Wire

Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card

5 months ago - GlobeNewsWire

Recommends A gainst E lecting WaterMill Nominee Jaime Vieser

5 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

5 months ago - Business Wire

Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation

5 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading proxy advisory fir...

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

5 months ago - Business Wire

ISS Acknowledges Ziopharm's Outperformance of its Peer Group During Chairman Scott Tarriff's Tenure

5 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

5 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

5 months ago - Business Wire

Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook

5 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

5 months ago - Business Wire

– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,  and a Confirmed Partial Response –

5 months ago - GlobeNewsWire

– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings –

5 months ago - GlobeNewsWire

– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director –

5 months ago - GlobeNewsWire

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a...

6 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Level One Partners, LLC, (“Level One Partners”) along with all of its related entities, will vote 100% of its approximately 10.68 million shares of Ziopharm Oncolo...

6 months ago - Business Wire

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

6 months ago - Business Wire

Urges Shareholders to Sign and Return Ziopharm's GREEN Consent Revocation Card

6 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially o...

6 months ago - Business Wire

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a prelimina...

6 months ago - GlobeNewsWire

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a...

7 months ago - GlobeNewsWire

This month's collection of penny stocks has little in common beyond rock-bottom prices and promising technical chart patterns.

Other stocks mentioned: BBAR, EDRY, EOD, GEN
7 months ago - Investopedia

– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively  as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva –

7 months ago - GlobeNewsWire

BOSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory...

7 months ago - GlobeNewsWire

One of the biotech's pipeline candidates won a key FDA designation.

7 months ago - The Motley Fool

BOSTON, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pedia...

7 months ago - GlobeNewsWire

BOSTON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate i...

8 months ago - GlobeNewsWire

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a...

9 months ago - GlobeNewsWire

– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech –

9 months ago - GlobeNewsWire

- RPM leverages the Sleeping Beauty system to reduce cost and simplify production for CD19-specific CAR-T infusion the day after gene transfer - - RPM leverages the Sleeping Beauty system to reduce cost...

10 months ago - GlobeNewsWire

About ZIOP

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner ... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
ZIOP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ZIOP stock is "Buy." The 12-month stock price forecast is 5.08, which is an increase of 67.66% from the latest price.

Price Target
$5.08
(67.66% upside)
Analyst Consensus: Buy